INSIDE TRACK CONFERENCE
*Third party registration should be used if you are requesting an individual registration for someone who is not you.
Please note that website registration under your name will be needed before registering someone else to this event.
Chair: O. Pagani, CH
Scientific committee: F. Cardoso, PT - N. Harbeck, DE - S. Paluch-Shimon, IL - A. Partridge, US - F. Peccatori, IT - E. Senkus, PL - Y. Wengström, SE
Breast cancer in young women is a complex disease, occurring when these women are at the peak of their reproductive years, family life and careers. Being a somewhat rare disease the optimal management of these patients is based on scientific data derived from clinical trials mostly conducted on older women. Many aspects of breast cancer in young women are therefore poorly understood (e.g. etiology and biology among others) and research is much needed in this field. In addition, young women have many years ahead of them to suffer the long-term effects of treatment and specific survivorship issues (fertility and job among others). This fourth conference is a new opportunity for the latest updates on this field and a platform for generating future research concepts and collaborations. It will cover epidemiology, molecular biology, genetics, pathology, surgery, radiotherapy, systemic therapy, survivorship issues in young women with breast cancer.
It will also include a Consensus Session that will form the basis for a Consensus Guidelines manuscript to be published after the Conference.
• In depth learning and update of the scientific and clinical aspects of breast cancer in young women
• Highlight the importance of multi-disciplinary management and discuss difficult clinical cases
• Focus on clinical research priorities and future perspectives, involving patients’ advocates in setting the agenda
• Participate in the discussion of consensus guidelines
• Epidemiology of early and advanced disease
• Hereditary breast cancer
• Diagnostic tools and challenges
• Loco-regional therapy
• Systemic therapy
• Psychosocial aspects and survivorship
The Conference is an ESO-ESMO joint event.
|Held under the patronage of|
O. Abulkhair, King Abdulaziz Medical City for National Guard, Riyadh, SA
L. Audergon, Comano, CH
H.A. Azim Jr., American University of Beirut, Beirut, LB
L. Baider, Assuta Medical Center, Tel-Aviv, IL
G. Bianchi Micheli, Southern Switzerland Breast Center (CSSI), Viganello, Lugano, CH
S. Bober, Dana-Farber Cancer Institute, Boston, US
C. Canonica, Bellinzona and Valleys Regional Hospital, Bellinzona, CH
F. Cardoso, Champalimaud Clinical Center, Lisbon, PT
M.J. Cardoso, Champalimaud Clinical Center, Lisbon, PT
S. Cima, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
R. Condorelli, Locarno Regional Hospital, Locarno, CH
M. Conti Beltraminelli, Italian Hospital, Viganello, Lugano, CH
G. Curigliano, European Institute of Oncology, Milan, IT
S. Di Lascio, Mendrisio Regional Hospital, Mendrisio, CH
N.S. El Saghir, American University of Beirut Medical Center, Beirut, LB
S. Gal, Jerusalem, IL
J. Garber, Dana Farber Cancer Institute Boston, US
K. Gelmon, BC Cancer Agency, Vancouver, CA
A. Gorini, Milan University, Milan, IT
R. Graffeo, Oncology Institute of Southern Switzerland (IOSI), Lugano, CH
S. Han, UZ Leuven, Lauven, BE
N. Harbeck, University of Munich (LMU), Munich, DE
B. Kaufman, Sheba Medical Center, Ramat Gan, IL
M. Lambertini, Institut Jules Bordet, Brussels, BE
K. Lång, Lund University, Malmö, SE
F. Meani, Lugano Regional Hospital, Lugano, CH
J. Merschdorf, Young Survival Coalition, New York, US
C. O'Brien, St James's Hospital, Dublin, IE
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Bellizona, CH
S. Paluch-Shimon, Shani Shaare Zedek Medical Centre, Jerusalem, IL
A.H. Partridge, Dana-Farber Cancer Institute, Boston, US
F.A. Peccatori, European Institute of Oncology, Milan, IT
P. Poortmans, Institut Curie, Paris, FR
G. Pravettoni, European Institute of Oncology, Milan, IT
G. Pruneri, National Cancer Institute - Foundation IRCCS, Milan, IT
A. Richetti, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
K. Rosenzweig, Kfar Saba, IL
A. Santi, Locarno Regional Hospital, Locarno, CH
M. Schilstra, NL
E. Senkus, Medical University of Gdansk, Gdansk, PL
B. Sirohi, Barts Health NHS Trust, London, UK
T. Spanic, Europa Donna Slovenia, Ljubljana, SI
S. Spitz, EuropaDonna, Vienna, AT
V. Stearns, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, US
M. Taborelli, Italian Hospital, Viganello, Lugano, CH
M. Valli, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
I. Vaz-Luis, Gustave Roussy Institute, Villejuif, FR
V.A. Vitale, Southern Switzerland Breast Center (CSSI), Viganello, Lugano, CH
Y. Wengström, Karolinska Institutet & Cancer Theme, Karolinska University Hospital, Huddinge, SE
J. Winterling, Karolinska University Hospital, Stockholm, SE
S. Zehbe, Bellinzona and Valleys Regional Hospital, Bellinzona, CH
S. Zuckerman, Shaare Zedek Medical Center, Jerusalem, IL
Organisation and Programme
Francesca Marangoni (1)
phone: +39 02 85464525
Registrations and Abstracts
Alice Ciocchini (1)
phone: +39 02 85464529
Sponsorship and travel grants
Luis Carvalho (2)
phone: +41 91 8200958
Corinne Hall (1)
phone: +39 02 85464522
phone: +41 91 8200955
(1) European School of Oncology, Via Turati 29, 20123 Milan, Italy
(2) European School of Oncology, Piazza Indipendenza 2, 6500 Bellinzona, Switzerland
Palazzo dei Congressi Lugano
Piazza Indipendenza 4
The official language will be English. No translation will be provided.
The organisers bear no responsibility for ontoward events in relation to the participation in the Conference. Participants are advised to take out their own personal and travel insurance coverage.
An abstract book will be published as supplement to The Breast and will contain abstracts of the invited lecturers and those submitted by the participants that have been accepted for oral or poster presentation or for publication only. The best abstracts have been selected and proposed for oral presentation (Free registration will be granted to the first author of the selected abstracts). Oral presentations will be scheduled on 8 October while poster session will be scheduled on 7 October.
CME ACCREDITATION CERTIFICATES
Participants will be issued a certificate of attendance.
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value. The event is designated for a maximum of 16 European CME credits (ECMEC). Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
The programme was furthermore awarded with 14 cat. 1 ESMO-MORA points.
Free Wi-Fi internet access in all areas of the BCY4 venue is available.
WLAN SSID: PalazzoCongressi
FILMING, AUDIOGTAPING AND PHOTOGRAPHS
Please note that capturing contents of the sessions is prohibited.
REGISTRATION DESKS, OPENING HOURS
Saturday, 6 October (10:00 - 19:00)
Sunday, 7 October (8:00 - 19:20)
Monday, 8 October (8:00 - 14:00)
EXHIBITION, OPENING HOURS
Saturday, 6 October (12:00 - 19:00)
Sunday, 7 October (8:00 - 19:10)
Monday, 8 October (8:00 - 13:00)
FACULTY AND PANEL MEMBERS
Members of the faculty are invited to refer to the Faculty Room (first floor).
Travel grants have been made available on a competitive basis.
ESO is particularly grateful to the ABC Global Alliance, Amgen and the Breast Cancer Research Foundation for having provided grants to support the participation of several participants.
SPONSORED SATELLITE SYMPOSIA
BCY CONFERENCE AND CONSENSUS GUIDELINES
Breast Cancer in Young Women Conference (BCY1)
8-10 November 2012
The guidelines are published in The Breast 23 (2014) 209-220
2nd Breast Cancer in Young Women Conference (BCY2)
4-5 November 2014
The guidelines are published in The Breast 26 (2016) 87-99
3rd ESO-ESMO Breast Cancer in Young Women International Conference (BCY3)
10-12 November 2016
The guidelines are published in The Breast 26 (2017), Volume 35, pages 203–217
Session 5 on Fertility and Pregnancy is supported by Dana-Farber Cancer Institute while the Nursing session is held in collaboration with EONS.
ESO wishes to express its appreciation to the following sponsors for having granted their participation and support to BCY4:
|Late registration by:||23 September 2018|
|Save event date:||06 October 2018|
• Medical oncologists
• Radiation oncologists
• Breast radiologists
• Patient advocates
Registration may be carried out online (available at the top of this page) or by returning the registration form.
Registration includes participation in all sessions, a copy of the Programme and the Abstract Book, coffee breaks and lunch as indicated in the programme.
* BreastCentresNetwork, Club ESO and ESMO Members
• Registration to the Patient Advocates workshop only: 50€
• Registration form to be requested to firstname.lastname@example.org
CANCELLATION OF REGISTRATION OR REPLACEMENT
(applicable only for individual registrations)
Cancellation should be notified to ESO in writing. In case of cancellation without replacement, the fee less handling charges of EUR 100 will be refunded within two months from notification, provided that the cancellation is received by ESO before 14 September 2018. Replacements will be possible till 23 September 2018.
CONFIRMATION OF REGISTRATION
Registration will be confirmed by e-mail.
The badge is the only official evidence of registration and should be worn at all times during the event. Loss of badge causes loss of registration.
NURSES AND PATIENT ADVOCATES
Nurses and representatives of cancer patient advocacy non-profit organizations are eligible for a discounted registration fee:
EUR 200 by 17 June, EUR 250 by 23 September, EUR 300 from 24 September and onsite.
Interested nurses and patient advocates should register online and then provide the requested documents by email to Alice Ciocchini (email@example.com) within one week, in order to complete the registration. Should we not receive the documents within the deadline, the registration will not be confirmed.
Requested documents are:
• Nurses: please provide your curriculum vitae with full contact details.
• Patient advocates: please provide your curriculum vitae or resume indicating your advocacy experience, role within the organisation and the full contact details of the patient advocate organisation.
Patient Advocates registration to the BCY4 conference includes participation in the Patient Advocates workshop scheduled on 8 October from 14.00 to 18.30.
It is nevertheless possibile for interested Patient Advocates to paticipate in the metioned workshop only. Registration to the workshop is required and the cost is 50€ (lunch and coffee break included). For further details and registration, please contact Alice Ciocchini (firstname.lastname@example.org).
The conference is open to representatives of print and electronic media. Registration is free of charge to journalists who are in possession of a valid, recognised press card. Freelance journalists must present a commissioning letter on headed paper from a recognised news organisation or publication. Representatives of advertising, marketing and public relations companies are not eligible for free media registration. A copy of the Press Card or of the commissioning letter should be sent, together with the media registration form, to Alice Ciocchini (email@example.com).
Group registration may be processed online for groups of 5 or more individuals and is available at the bottom of this page. Further instructions can also be found here.
For hotel accommodation in Lugano, please book online at http://bit.ly/2z0GLxo
| OPENING SESSION Chair: O. Pagani, CH
|12:00||Welcome by Cantonal Authorities
Pres. P. Kandemir Bordoli, CH - On. C. Zanini Barzaghi, CH
|12:15||KEYNOTE 1: Presentation by young patient
L. Audergon, CH
|12:30||KEYNOTE 2: Treating breast cancer in different ethnic populations
L. Baider, IL [Abs IN2]
|SESSION 1: TUMOR BIOLOGY
Chair: G. Pruneri, IT
|13:00||Clinical utility of genomic tests in young women with breast cancer
H.A. Azim Jr., LB [Abs IN3]
|SESSION 2: FAMILIAL AND HEREDITARY BREAST CANCER
Chairs: R. Graffeo, CH - M. Taborelli, CH
|13:20||Clinical management of women harboring low-moderate risk genes: any guideline?
J. Garber, US
|13:40||Systemic therapies in BRCA+ breast cancer - what's new?
S. Paluch-Shimon, IL
|14:00||Ethical dilemmas around genetic testing
S. Zuckerman, IL [Abs IN6]
|SESSION 3: NEOADJUVANT THERAPIES AND LOCO-REGIONAL TREATMENT
Chairs: A. Richetti, CH - S. Zehbe, CH
|15:10||Indications to neoadjuvant chemotherapy and tailored strategies
N. Harbeck, DE [Abs IN7]
|15:30||Challenges for the radiologist
K. Lång, SE [Abs IN8]
|15:45||Challenges for the onco-plastic surgeon
M.J. Cardoso, PT
|16:05||Challenges for the pathologist
G. Pruneri [Abs IN10]
|16:20||Challenges for the radiation oncologist
P. Poortmans, FR [Abs IN11]
|NURSING SESSION: SUPPORTIVE CARE - REHABILITATION
(held in collaboration with EONS)
Chair: Y. Wengström, SE
Y. Wengström, SE
|17:05||Psychosocial needs and care for young women
J. Winterling, SE [Abs IN12]
|17:25||Physical activity during treatment for breast cancer
Y. Wengström, SE [Abs IN13]
|18:00||Satellite symposium 1|
|8:30||PATIENT ADVOCACY AGENDA
Chairs: J. Merschdorf, US - T. Spanic, SI
|SESSION 4: SYSTEMIC THERAPIES
Chairs: M. Conti Beltraminelli, CH - O. Abulkhair, SA
|9:15||News in adjuvant therapy of HR+ disease
O. Pagani, CH
|9:30||News in adjuvant therapy of triple negative and HER2+ disease
G. Curigliano, IT
|9:45||News in the management of ABC
F. Cardoso, PT
|10:00||Treatment adherence: any real impact on outcomes?
B. Kaufman, IL
|10:15||Long-term side effects: the wolf in the cage
I. Vaz-Luis, FR [Abs IN20]
|10:40||Magnitude of clinical benefit: anything different in young women?
E. Senkus, PL [Abs IN21]
|SESSION 5: FERTILITY AND PREGNANCY
(session supported by Dana-Farber Cancer Institute)
Chairs: A. Santi, CH - C. Canonica, CH
|11:30||Pregnancy during breast cancer: any news?
S. Han, BE
|11:45||Sexual life after breast cancer
S. Bober, US [Abs IN23]
|12:05||Maternity after breast cancer
V. Stearns, US
|12:25||Physicians attitudes and knowledge about fertility preservation
M. Lambertini, IT [Abs IN25]
|12:55||Research priorities: summary of BCYR1
A.H. Partridge, US
|13:05||Lunch and poster session|
|SESSION 6: ROUNDTABLE - MINORITY REPORTS: THE PATIENTS’ VOICE
Chairs: K. Gelmon, CA - S. Paluch-Shimon, IL
S. Gal, IL - K. Rosenzweig, IL - M. Schilstra, NL - S. Spitz, CH
|SESSION 7: FOLLOW-UP CARE
Chairs: F.A. Peccatori, IT - Y. Wengström, SE
|15:00||Follow-up clinics: nurses to lead them?
Y. Wengström, SE
|15:20||Remote programs for follow-up
C. O'Brien, IE [Abs IN30]
|15:40||Return to work: hope or reality?
A. Gorini, IT [Abs IN31]
|SESSION 8: SURVIVORSHIP AND QUALITY OF LIFE ISSUES
Chairs: A.H. Partridge, US - S. Di Lascio, CH
|16:50||Support groups in the post treatment phase
G. Bianchi Micheli, CH [Abs IN32]
|17:10||Management children, partners and relatives
G. Pravettoni, IT
|17:30||Access to care
N.S. El Saghir, LB [Abs IN34]
|17:50||How to implement guidelines in low-middle income contries
B. Sirohi, UK
|18:20||Satellite symposium 2|
|SESSION 9: CASE DISCUSSION|
|8:30||Case Discussion - early breast cancer
Chairs: R. Condorelli, CH - M. Valli, CH - F. Meani, CH
|9:15||Case Discussion - advanced breast cancer
Chairs: O. Abulkhair, SA - K. Gelmon, CA - P. Poortmans, FR - V. Vitale, CH
|10:00||Best abstracts presentation
Chair: S. Cima, CH
N. Harbeck, DE - S. Rosenberg, US - K. Smith, US - R. Yerushalmi, IL
|10:50||Summary statement on behalf of the Young Women Advocates|
|11:00||SESSION 10: BREAST CANCER IN YOUNG WOMEN INTERNATIONAL CONFERENCE STATEMENTS
Panelists: O. Abulkhair, SA - H.A. Azim Jr., LB - G. Bianchi Micheli, CH - F. Cardoso, PT - M.J. Cardoso, PT - G. Curigliano, IT - K. Gelmon, CA - N. Harbeck, DE - J. Merschdorf, US - O. Pagani, CH - S. Paluch-Shimon, IL - A.H. Partridge, US - F.A. Peccatori, IT - P. Poortmans, FR - G. Pruneri, IT - E. Senkus, PL - T. Spanic, SI - V. Stearns, US - Y. Wengström, SE
|13:00||Close of the BCY4 conference
|WORKSHOP for Patient Advocates: What advocates should know about breast cancer in young women (Wrap up session in collaboration with Europa Donna and the Young Survival Coalition)|
|14:00||Principles of systemic therapies in advanced breast cancer and the Global Alliance project
V.A. Vitale, CH [Abs IN36]
|14:45||Principles of genetic predisposition and counselling
S. Paluch-Shimon, IL
|15:05||How to interpret the pathology report
G. Pruneri, IT [Abs IN38]
|15:20||Principles of surgery
F. Meani, CH [Abs IN39]
|15:40||Principles of radiation therapy
E. Senkus, PL [Abs IN40]
|16:00||Questions and answers|
|17:00||Principles of systemic therapies in early breast cancer and management of early and late treatment side effects
K. Gelmon, CA [Abs IN41]
|17:30||The importance of multidisciplinary care
O. Pagani, CH
|17:45||Principles of clinical research
A. Partridge, US
|18:00||Questions and answers|
A/V RECORDING DURING THE CONFERENCE IS PROHIBITED
A prefix has been added to the abstract number to identify the type of presentation or acceptance:
OR: Abstract accepted for oral presentation.
BP: Abstracts identified as best posters.
PO: Abstracts accepted for poster presentations.
OR52 Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): subgroup analysis of 2 randomized phase 3 studies. Cristofanilli Massimo, USA
OR53 A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age. Yerushalmi Rinat, Israel
OR92 Understanding surgical decision-making in newly diagnosed young women with early-stage breast cancer.
Rosenberg Shoshana, USA
OR93 Patient-reported outcomes and factors associated with early discontinuation of adjuvant endocrine therapy in
premenopausal women with breast cancer. Smith Karen, USA
BP54 Differences in breast cancer stage at diagnosis by ethnicity, insurance status and family income in young woman in the United States. Franzoi Maria Alice, Brazil
PO45 Challenges in India about breast cancer & breast reconstruction. Maudgal Shubha, India
PO46 Better palliative care for terminal cancer patients in rural India - an NGO based approach. Mandal Nabanita, India
PO47 Breast health awareness in an Arabic culture: a qualitative exploration. Madkhali Norah, Saudi Arabia
PO48 Know your legal rights: education for young women diagnosed with breast cancer. Merschdorf Jennifer, USA
PO49 Knowledge, attitude and preventive measures for breast cancer among health care professionals at Bolan Medical Complex Hospital Quetta. Jogezai Pari Gul, Pakistan
PO51 Co-Survivors: a continuing need for education and support. Merschdorf Jennifer, USA
PO55 Incidence and prognosis of pregnancy-associated breast cancer: time-trends study from the nationwide Korean breast cancer registry database. Bae Soo Youn, South Korea
PO56 Localized triple negative breast cancer in young patients. Oualla Karima, Marocco
PO57 Analysis of the comparative characteristics of various neoadjuvant chemotherapy regimens for breast cancer patients associated with a BRCA1 mutation. Gigolaeva Larisa, Russian Federation
PO58 Prognostic factors of breast cancer in Algerian young women ≤ 35 years: about 578 cases. Guendouz Hamida, Algeria
PO59 Comparison of outcomes in young and very young women with breast cancer. Yadav Budhi Singh, India
PO60 Neoadjuvant chemotherapy treatment of breast cancer in young women in Albania. Malaj Besmira, Albania
PO61 The statistical interpretation of SBR grade severity and Ki-67 in young women with breast cancer in Morocco.
Akhouayri Laila, Marocco
PO62 Breast cancer in young women and coverage with mass screening. Ninashvili Nanuli, Georgia
PO63 Adjuvant radiation therapy in young breast cancer patients: current state of the art and evidence-based algorithm. Meattini Icro, Italy
PO64 Correlation of imaging features with clinicopathological features and immunohistochemical subtypes in young breast cancer women. Mehmood Tahir, Pakistan
PO65 Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME MBC cohort. Frank Sophie, France
PO66 Prognostic factors of disease progression in young breast cancer patients. Kozma Elvisa, Albania
PO67 Inadequate treatment still a major problem for Indonesian young age breast cancer patients: a single institutional experience. Salim Adrian, Indonesia
PO68 Adjuvant chemotherapy in young breast cancer patients with endrocrine receptor (ER) disease. Luz Paulo, Portugal
PO69 Breast cancer in young women: understanding our reality. da Silva Dias David, Portugal
PO70 Clinicopathological features of young women (≤39 years old) with invasive breast cancer. Utsumi Toshiaki, Japan
PO71 Modern chemotherapy use among young women with early-stage ER+/HER2- breast cancer. Poorvu Philip, USA
PO72 The effect of symbiotic gut bacterial differences in young breast cancer patients. An Jeongshin, South Korea
PO73 Heterogeneity of triple negative breast cancer occurring in young women: an immunohistochemical analysis.
Tsvetkova Vassilena, Italy
PO74 Pregnancy-associated breast cancer (PABC) in young Tunisian women: aggressive features and poor outcome.
Mejri Turki Nesrine, Tunisia
PO75 Differences in histological markers expression in early stage breast cancer in young women ( 40 years) according to Nottingham Prognostic Index classification. Mejri Turki Nesrine, Tunisia
PO76 A postpartum diagnosis increases risk for and determines an altered profile of metastasis in young women’s breast cancer. Borges Virginia, USA
PO94 Knowledge and health beliefs about breast cancer screening among rural Palestinian women: pilot study.
Saca-Hazboun Hanan, Palestinian Terrirories
PO95 The impact of chemotherapy and radiotherapy for breast cancer on cognition and functional performance. Potter Ann Marie, USA
PO96 Only a few young patients aged 40 years with ‘high-risk’ breast cancer preserved fertility; report from actual survey in a Japanese cancer hospital. Kataoka Akemi, Japan
PO97 Young breast cancer survivors and insomnia: a multicenter Swiss snapshot. Rossi Lorenzo, Switzerland
PO98 Treatment satisfaction in young women receiving palbociclib combination therapies for advanced/metastatic breast cancer in multiple countries globally. Iyer Shrividya, USA
PO99 Patient-reported outcomes (PROs) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA HR+/ HER2- subpopulation. Hurvitz Sara A., USA
PO100 Clinical outcomes, treatment patterns and health resource utilization (HRU) in triple negative metastatic breast cancer (mTNBC): a comparison between younger and older patients (pts) with germline BRCA mutation (gBRCAm). Quek Ruben G.W., USA
PO101 A systemic review of information requirements of young women with breast cancer undergoing mastectomy or breast conserving surgery. Mehmood Tahir, Pakistan
PO102 Evaluation of depression and anxiety in young women with metastatic breast cancer. Mehmood Tahir, Pakistan
PO103 Literature review of partner support and anxiety in young women with breast cancer. Mehmood Tahir, Pakistan
PO104 Characterization of young Mexican patients with breast cancer who underwent oocyte/embryo preservation. Villarreal-Garza Cynthia Mayte, Mexico
PO105 Follow-up status, patient retention and data collection of the "Joven & Fuerte" cohort for young women with breast cancer in Mexico. Villarreal Garza Cynthia Mayte, Mexico
PO106 The special concerns of young breast cancer patients before neo/adjuvant chemotherapy. Pogoda Katarzyna, Poland
PO108 Fertility preservation provision for breast cancer patients in England - a postcode lottery. Dash Isabella, UK